I'm pretty sure none of the guidelines apply to us, since we are targeting CCR5 with our antibody, not the SARS-CoV-2 virus directly.

All these things don't apply for leronlimab:

Quote:

---

Use of two robust orthogonal virus clearance steps

for monoclonal antibody products targeting SARS-CoV-2 proteins

characterize the impact of amino acid changes, insertions, or deletions throughout the monoclonal antibody target protein to identify regions where changes specifically impact monoclonal antibody binding or activity

Sponsors should characterize the epitopes to which monoclonal antibody products bind

---

etc ...

These guidelines are for neutralizing antibodies that target SARS2 proteins.